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Paul M. Vanhoutte initiated the first international sympo-
sium on the Mechanisms of Vasodilatation (MOVD) in 
Antwerp in 1977. This was to be followed by a series of 
MOVD meetings held all over the world (Table  1). Not 
only nitric oxide, but also endothelium-dependent hyper-
polarization (EDH), was extensively discussed during these 
meetings, and soon separate EDH meetings were organized 
in parallel, the majority of them in France (Table 2). After 
12 MOVD meetings and 7 EDH meetings, in 2019, the 
two were combined for the first time in Rotterdam, The 
Netherlands (20-22 May). There were around 90 partici-
pants. Sadly, it turned out to be the last meeting that Paul 
Vanhoutte could attend, since he passed away on 23 August 
2019. As always, he was sitting on the front row and stimu-
lating every speaker with multiple thoughtful questions. He 
also provided what he called his swan song, entitled “NO, 
from good to bad”. Unfortunately, he was correct. In this 
talk, he described that the well-known enhanced contrac-
tions after hypoxia also involve endothelial NO, yet instead 
of being a vasorelaxant agent acting via guanosine-3′,5′-cy-
clic monophosphate (cyclic GMP), now causing constric-
tion by stimulating biased activity of soluble guanylyl 
cyclase, resulting in the generation of inosine-3′,5′-cyclic 
monophosphate (cyclic IMP).1
In addition, 6 invited speakers provided lectures named 
after giants in the vascular field. In the Robert F Furchgott 
lecture, Min-Hui Zou (Atlanta, USA) discussed how ade-
nosine monophosphate-activated protein kinase, a sensor 
of redox status, results in vascular disease when dysfunc-
tional. Rhian Touyz (Glasgow, UK) gave the David F Bohr 
lecture. She introduced the novel reactive oxygen species–
generating Nox 5 and its role in vascular smooth muscle 
cells (VSMC). Claire Peppiatt-Wildman (Kent, UK), pro-
viding the Björn Folkow lecture, revealed to what extent 
pericytes in renal capillaries mimic VSMC, displaying 
T A B L E  1  MOVD meetings since 1977
Year Location Organizers
1977 Wilrijk, Belgium PM Vanhoutte and I Leusen
1980 Wilrijk, Belgium PM Vanhoutte and I Leusen
1983 Sydney, Australia PM Vanhoutte and S Vatner
1986 Rochester, USA PM Vanhoutte
1989 Strasbourg, France JC Stoclet and PM Vanhoutte
1993 Glasgow, United Kingdom I McGrath and PM Vanhoutte
1997 Maastricht, The Netherlands JGR De Mey and PM Vanhoutte
2001 Boston, USA RA Cohen and PM Vanhoutte
2005 Wilrijk, Belgium A Herman and PM Vanhoutte
2009 Sendai, Japan H Shimokawa and PM Vanhoutte
2013 Zurich, Switzerland TF Lüscher and PM Vanhoutte
2016 Rochester, USA VM Miller, RC Webb and PM Vanhoutte
2019 Rotterdam, The Netherlands AHJ Danser, JGR De Mey, U Simonsen, 
BE Isakson and PM Vanhoutte
2021 Hong Kong, China Y Wang, S Leung, Y Huang, AHJ Danser, 
JGR De Mey and RE Widdop
Note: The 2019 meeting was a joint MOVD/EDH meeting.
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among others relaxant responses to NO and constrictor 
responses to endothelin-1. In her Paul M Vanhoutte lec-
ture, Yu Wang (Hong Kong, China) suggested that the 
pro-inflammatory molecule lipocalin-2 (also known as 
neutrophil gelatinase-associated lipocalin) contributes to 
obesity-associated pathologies and may thus be a novel 
drug target.2 The lecture named after John T Shepherd 
(born on 21 May 1919, ie exactly 100  years before this 
meeting) was given by Mark Chapleau (Iowa City, USA). 
He focused on mechanoelectrical transduction, particu-
larly in relation to the baroreceptor reflex and discussed 
novel roles for hydrogen peroxide and the PIEZO channels 
in baroreceptor activity. Finally, the lecture linked to EDH 
(named after Tudor Griffith) was given by Steven Segal 
(Columbia, USA) who illustrated how hyperpolarization 
is conducted along the endothelium and into surrounding 
VSMC via gap junctions, while ion channels activated by 
oxidative stress or the sympathetic nervous system coun-
terbalance this phenomenon.
Three symposia were devoted, respectively, to ageing, 
pre-eclampsia and gender aspects. Ageing VSMC change 
their phenotype from contractile to synthetic and osteo-
chondrocytic, hence the greater risk of vascular calcifi-
cation in the elderly. Defective maturation of laminin A, 
normally responsible for nuclear pore formation and chro-
matin organization, results in pre-laminin A accumulation, 
which induces DNA damage, apoptosis and senescence 
(Catherine Shanahan, London, UK). Removing senescent 
cells with senolytic drugs increases a healthy life span 
(Darren Baker, Rochester, USA),3 while reduced activity 
of DNA repair enzymes does the opposite (Anton Roks, 
Rotterdam, The Netherlands).4 The mitochondrial adaptor 
protein p66(Shc) and the deacetylating sirtuins additionally 
regulate the ageing process, while endothelial NO synthase 
contributes by generating reactive oxygen species (Thomas 
Lüscher, London, UK).5
Ravi Thadhani (Los Angeles, USA) discussed the angio-
genic imbalance in pre-eclampsia, resulting from the placen-
tal release of the soluble receptor, soluble fms–like tyrosine 
kinase (sFlt)-1, which binds and inactivates vascular endo-
thelial growth factor (VEGF). Given the important vascular 
and renal effects of VEGF, this results in endothelial dys-
function, endothelin-1 up-regulation, hypertension and pro-
teinuria. Not surprisingly, VEGF inhibitors used in cancer 
patients exert the same effects (Katrina Mirabito Colafella, 
Melbourne, Australia).6 Novel therapies for pre-eclampsia 
are now aimed at either removing sFlt-1 or inhibiting en-
dothelin-1. Sandra Davidge (Edmonton, Canada) provided 
evidence for an additional role for lectin-like oxidized LDL 
receptor-1 in the sFlt-1 up-regulation.
Virginia Miller (Rochester, USA) stressed the importance 
of stratifying one's experiments according to sex, given the 
multiple male/female differences. Ultimately, this may imply 
that men and women require different drugs and/or differ-
ent doses. Yet, Peter Bie (Odense, Denmark) warned that we 
should not forget our original research goal, which may well 
be sex-independent, and thus adding sex as an additional pa-
rameter would at most complicate things and increase ani-
mal numbers unnecessarily.7 Hester den Ruijter (Utrecht, The 
Netherlands), making use of the adverse drug reaction (ADR) 
database of Uppsala Monitoring Centre (currently containing 
19 million ADR reports!), revealed that women report more 
ADRs, with men predominantly reporting serious ADRs. The 
difference is, therefore, due to less serious ADR. Whether 
this implies that women experience more ADR cannot yet 
be concluded from these data. Finally, Susan Leung (Hong 
Kong, China) explained how oestradiol up-regulates both 
NO- and EDH-type relaxations and was able to link this to 
male/female vascular responsiveness differences in aged and 
diseased animals.
The remainder of the programme consisted of approx-
imately 50 free communications, either as poster or oral 
T A B L E  2  EDH meetings since 1995
Year Location Organizers
1995 Vaux de Cernay, France M Félétou and PM Vanhoutte
1998 Vaux de Cernay, France M Félétou and PM Vanhoutte
2000 Vaux de Cernay, France M Félétou and PM Vanhoutte
2002 Vaux de Cernay, France M Félétou and PM Vanhoutte
2008 Tampere, Finland E Moilanen, I Pörsti, H Vapaatalo and 
PM Vanhoutte
2012 Vaux de Cernay, France M Félétou and PM Vanhoutte
2015 Nyborg, Denmark JGR De Mey, P Hansen and  
PM Vanhoutte
2019 Rotterdam, The Netherlands AHJ Danser, JGR De Mey, U Simonsen, 
BE Isakson and PM Vanhoutte
Note: Initially, this meeting was known as endothelium-derived hyperpolarizing factor (EDHF) meeting. The 2019 meeting was a joint MOVD/EDH meeting.
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presentation. This issue contains the papers that were sub-
mitted by the invited speakers and three additional abstract 
presenters.8-10
The next MOVD meeting will be held in fond memory of 
Paul M. Vanhoutte in his “own” university city (since 2006) 
Hong Kong (http://movd2 021.hku.hk), where he remained 
permanent Visiting Professor until his death.
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